Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: A pilot study

Scandinavian Journal of Infectious Diseases

Volumn 34, Issue 7, 2002, Pages 505-511

  Sangfelt, Per ^a   Uhnoo, Ingrid ^a   Hollander, Anna ^a   Lindh, Gudrun ^a   Weiland, Ola ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; FAMCICLOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PREDNISOLONE; VIRUS DNA; 2 AMINOPURINE; ANTIVIRUS AGENT; DRUG DERIVATIVE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MEDICAL ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT OUTCOME; BLOOD; DRUG COMBINATION; ISOLATION AND PURIFICATION; MIDDLE AGED;

2-AMINOPURINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMAN; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGE; PILOT PROJECTS; SUPPORT, NON-U.S. GOV'T; HUMANS; MIDDLE AGED;

EID: 0035990778     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540110080764     Document Type: Article

References (30)

1. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
2. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
3. Lamivudine as initial treatment for chronic hepatitis B in the US
4. Lamivudine (100mg od) for 1 y significantly improves necroinflammatory activity and reduces progression in fibrotic stage: Results of a placebo-controlled multicenter study in Asia of lamivudine for chronic hepatitis B infection
5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 y of therapy
6. A one-year trial of lamivudine for chronic hepatitis B
7. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
8. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine] in vitro
9. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthoptic liver transplantation
10. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
11. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
12. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
13. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
14. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus
15. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
16. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
17. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infections: A randomised trial
18. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone results of a pilot study
19. Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test
20. Histological and virological long-term outcome in patients treated with a combination of interferon alfa-2b and ribavirin for chronic hepatitis C
21. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials
22. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
23. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?
24. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B virus infection
25. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B
26. Long-term remission of chronic hepatitis B after alfa-interferon therapy
27. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
28. Long-term therapy of chronic hepatitis B with lamivudine
29. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
30. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study